ClinicalTrials.gg

Program

tacabrutideg

Also written as “Tacabrutideg”, “BGB-16673” and “[14C]-BGB-16673”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell, Marginal Zone · Chronic Urticaria, led by BeOne Medicines.

Furthest: phase 3, since Feb 21, 20258 company-led studies, 7 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeOne Medicines87 open or runningphase 3since Feb 21, 2025Aug 9, 2021Nov 30, 2026phase 1 · NCT07005713

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 9, 2021First study: phase 2 study in Lymphoma, B-Cell, Marginal ZoneFirst studyNCT05006716 · 689 planned · United States, Australia, Brazil and more
  2. Feb 22, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05294731 · 146 planned · China
  3. Jan 10, 2025Phase 1 study in Healthy VolunteersNCT06776679 · 8 enrolled · United States
  4. Feb 21, 2025Phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT06846671 · 250 planned · United States, Argentina, Australia and more
  5. May 6, 20252 phase 3 studies in Leukemia, Lymphocytic, Chronic, B-CellNCT06970743, NCT06973187
  6. May 22, 2025Phase 1 study in Chronic UrticariaNCT07005713 · 58 planned · China
  7. Sep 29, 2026Phase 1 study in Hepatic ImpairmentNCT07856004 · 24 planned
  8. Oct 5, 2026Primary completion moved from 2026-11 to 2027-03Date moved laterphase 2 · +4 months · NCT05006716

Ahead

  1. Nov 30, 2026Primary completion: phase 1 study in Chronic UrticariaNCT07005713
  2. Mar 2027Primary completion: phase 2 study in Lymphoma, B-Cell, Marginal ZoneNCT05006716
  3. Jun 30, 2027Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT05294731
  4. Jul 31, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07856004

TargetBeta

BTK →read by rule
“An orally bioavailable, targeted degrader of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) by using the proteolysis targeting chimera (PROTAC) technology, ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07856004Hepatic Impairment1Not yet recruitingJul 31, 202724
NCT07005713Chronic Urticaria · China1RecruitingNov 30, 202658
NCT06973187Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3RecruitingApr 17, 2028500
NCT06970743Leukemia, Lymphocytic, Chronic, B-Cell · China, Taiwan3Active, not recruitingNov 30, 2029153
NCT06846671Leukemia, Lymphocytic, Chronic, B-Cell · United States, Argentina, Australia and more3RecruitingMay 15, 2028250
NCT06776679Healthy Volunteers · United States1CompletedMar 27, 20258
NCT05294731Lymphoma, Non-Hodgkin · China2RecruitingJun 30, 2027146
NCT05006716Lymphoma, B-Cell, Marginal Zone · United States, Australia, Brazil and more2RecruitingMar 2027689

How it is read

Names in the registry

  • “Tacabrutideg”, 6 entries
  • “BGB-16673”, 1 entry
  • “[14C]-BGB-16673”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.